Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Inhaled LIQ861 (Yutrepia) in PAH
NCT03992755Phase 3Active, not recruiting
- Sponsor
- Liquidia Corporation
- Start
- Jul 2019
- Primary completion
- May 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of treprostinil in pulmonary arterial hypertension (PAH), sponsored by Liquidia Corporation. Started Jul 2019; status: active, not recruiting.
02
Drugs
treprostinil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT03992755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03992755.